Jennison Associates LLC Syndax Pharmaceuticals Inc Transaction History

Jennison Associates LLC

  • $155 Billion
  • Q2 2024

A detailed history of Jennison Associates LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Jennison Associates LLC holds 51,334 shares of SNDX stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,334
Previous 50,170 2.32%
Holding current value
$1.01 Million
Previous $1.19 Million 11.81%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024
BUY
$18.82 - $23.79 $21,906 - $27,691
1,164 Added 2.32%
51,334 $1.05 Million
Q1 2024

May 02, 2024
SELL
$19.71 - $24.57 $12,023 - $14,987
-610 Reduced 1.2%
50,170 $1.19 Million
Q4 2023

Feb 01, 2024
SELL
$11.39 - $21.67 $26.2 Million - $49.8 Million
-2,296,893 Reduced 97.84%
50,780 $1.1 Million
Q3 2023

Oct 31, 2023
SELL
$14.52 - $21.77 $2.53 Million - $3.79 Million
-174,243 Reduced 6.91%
2,347,673 $34.1 Million
Q2 2023

Aug 03, 2023
BUY
$19.35 - $22.31 $2.04 Million - $2.35 Million
105,462 Added 4.36%
2,521,916 $52.8 Million
Q1 2023

Apr 26, 2023
BUY
$20.66 - $28.98 $2.36 Million - $3.31 Million
114,208 Added 4.96%
2,416,454 $51 Million
Q4 2022

Feb 09, 2023
BUY
$20.64 - $26.24 $13.5 Million - $17.1 Million
652,451 Added 39.55%
2,302,246 $58.6 Million
Q3 2022

Nov 01, 2022
BUY
$18.51 - $24.79 $30.5 Million - $40.9 Million
1,649,795 New
1,649,795 $39.6 Million
Q1 2018

Apr 20, 2018
SELL
$8.71 - $14.82 $4.63 Million - $7.87 Million
-531,028 Closed
0 $0
Q4 2017

Jan 25, 2018
SELL
$7.8 - $12.94 $3.28 Million - $5.45 Million
-420,870 Reduced 44.21%
531,028 $4.65 Million
Q3 2017

Nov 03, 2017
BUY
$10.9 - $12.73 $10.4 Million - $12.1 Million
951,898
951,898 $11.1 Million

Others Institutions Holding SNDX

# of Institutions
200
Shares Held
87M
Call Options Held
268K
Put Options Held
76.8K
View Full List

About Syndax Pharmaceuticals Inc

SNDX Quotes by TradingView
  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.11B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email